<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT03001414</url>
  </required_header>
  <id_info>
    <org_study_id>CT-PAH002</org_study_id>
    <nct_id>NCT03001414</nct_id>
  </id_info>
  <brief_title>Study of Angiogenic Cell Therapy for Progressive Pulmonary Hypertension: Intervention With Repeat Dosing of eNOS-enhanced EPCs</brief_title>
  <acronym>SAPPHIRE</acronym>
  <official_title>A Multicentre, Late Phase Clinical Trial to Establish the Efficacy and Safety of Repeat Dosing of Autologous Endothelial Progenitor Cells (EPCs) Transfected With Human Endothelial NO-synthase (eNOS) in Patients With Pulmonary Arterial Hypertension (PAH) on Top of Conventional Treatments</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northern Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ottawa Hospital Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Northern Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The SAPPHIRE clinical trial seeks to establish the efficacy and safety of repeated monthly&#xD;
      dosing of autologous EPCs transfected with human eNOS (heNOS) in patients with symptomatic&#xD;
      severe PAH on available PAH-targeted medical therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      SAPPHIRE will use autologous progenitor cell-based gene delivery to enhance lung&#xD;
      microvascular repair and regeneration in patients with severe symptomatic PAH. A total of 45&#xD;
      patients will be enrolled in this multi-centre, late phase, randomized, double-blind,&#xD;
      placebo-controlled, 3-arm protocol. Up to nine centres across Canada will participate.&#xD;
&#xD;
      Consented study participants who meet all eligibility criteria during the screening period&#xD;
      will be scheduled to undergo apheresis. Following successful apheresis collection and receipt&#xD;
      of the cell samples by the cell manufacturing facility, randomization will take place though&#xD;
      a web-based system. Manufacturing of the cell therapy product will then be performed by the&#xD;
      cell manufacturing facility according to the assigned treatment allocation:&#xD;
&#xD;
      Arm 1: Placebo (Plasma-Lyte A; 4 monthly IV infusions) in Course 1 (1st 6 months) followed by&#xD;
      Autologous EPCs transfected with human eNOS in Course 2 (2nd 6 months; 4 monthly IV&#xD;
      infusions)&#xD;
&#xD;
      Arm 2: Autologous EPCs transfected with human eNOS in Course 1 (1st 6 months; 4 monthly IV&#xD;
      infusions) followed by Placebo (Plasma-Lyte A) in Course 2 (2nd 6 months; 4 monthly IV&#xD;
      infusions)&#xD;
&#xD;
      Arm 3: Autologous EPCs transfected with human eNOS in Course 1 (1st 6 months; 4 monthly IV&#xD;
      infusions) followed by a repeat dosing with Autologous EPCs transfected with human eNOS in&#xD;
      Course 2 (2nd 6 months; 4 monthly IV infusions)&#xD;
&#xD;
      Approximately 5-9 days later, the study product will be transported to the investigative site&#xD;
      where the initial treatment will be delivered to the study participant in an outpatient&#xD;
      setting which is equipped for continuous monitoring of vital signs and oxygen saturation.&#xD;
      Participants will subsequently be monitored for a minimum of 1 hour and discharged from the&#xD;
      clinic once judged by the study investigator to be clinically stable.&#xD;
&#xD;
      Treatment and follow-up assessments will take place over a 12-month period (11 study visits&#xD;
      in total). Once the 12-month trial data collection is completed, the trial will convert to a&#xD;
      registry with the goal of collecting long-term safety information through annual telephone&#xD;
      contacts for 10 years. Participants will be permitted to enroll in other clinical trials&#xD;
      during the registry period.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 28, 2017</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in 6 Minute Walk Distance (6MWD) from Baseline</measure>
    <time_frame>6 months</time_frame>
    <description>Comparison of change from baseline after delivery of 4 doses of study product (Arms 2 and 3 versus Arm 1)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in 6 Minute Walk Distance (6MWD) from Baseline</measure>
    <time_frame>12 months</time_frame>
    <description>Comparison of change from baseline after delivery of 4 versus 8 doses of study product (Arms 1 versus Arm 3)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in 6 Minute Walk Distance (6MWD) from Baseline</measure>
    <time_frame>3 and 9 months</time_frame>
    <description>Comparison of change from baseline to assess durability of any measured improvement (Arm 2 only)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Pulmonary Vascular Resistance from Baseline</measure>
    <time_frame>6 months</time_frame>
    <description>Comparison of change from baseline after 4 doses of study product (Arms 2 and 3 versus Arm 1)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Pulmonary Vascular Resistance from Baseline</measure>
    <time_frame>12 months</time_frame>
    <description>Comparison of change from baseline after delivery of 4 versus 8 doses of study product (Arm 1 versus Arm 3)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Pulmonary Vascular Resistance from Baseline</measure>
    <time_frame>3 and 9 months</time_frame>
    <description>Comparison of change from baseline to assess durability of any measured improvement (Arm 2 only)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Deaths or Clinical Worsening of Pulmonary Arterial Hypertension</measure>
    <time_frame>6 months</time_frame>
    <description>Comparision of number measured from baseline (Arms 2 and 3 versus Arm 1). Clinical worsening will be defined by any of the following: all-cause mortality, hospitalization due to worsening cardiopulmonary status attributable to progression of disease, decrease in 6MWD by ≥ 15%, worsening of WHO functional class</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Deaths or Clinical Worsening of Pulmonary Arterial Hypertension</measure>
    <time_frame>12 months</time_frame>
    <description>Comparison of number measured from baseline after delivery of 4 versus 8 doses of study product (Arm 1 versus Arm 3). Clinical worsening will be defined by any of the following: all-cause mortality, hospitalization due to worsening cardiopulmonary status attributable to progression of disease, decrease in 6MWD by ≥ 15%, worsening of WHO functional class</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Echocardiography Right Ventricular (RV) Function Measures from Baseline</measure>
    <time_frame>6 months</time_frame>
    <description>Comparison of change from baseline after 4 doses of study product (Arms 2 and 3 versus Arm 1)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Echocardiography Right Ventricular (RV) Function Measures from Baseline</measure>
    <time_frame>12 months</time_frame>
    <description>Comparison of change from baseline after delivery of 4 versus 8 doses of study product (Arm 1 versus Arm 3)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Magnetic Resonance Imaging Right Ventricular (RV) Function Measures from Baseline</measure>
    <time_frame>6 months</time_frame>
    <description>Comparison of change from baseline after delivery of 4 doses of study product (Arms 2 and 3 versus Arm 1)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Magnetic Resonance Imaging Right Ventricular (RV) Function Measures from Baseline</measure>
    <time_frame>12 months</time_frame>
    <description>Comparison of change from baseline after delivery of 4 versus 8 doses of study product (Arm 1 versus Arm 3)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Quality of Life Measures from Baseline</measure>
    <time_frame>6 months</time_frame>
    <description>Comparison of change from baseline measured by SF-36 Survey after delivery of 4 doses of study product (Arms 2 and 3 versus Arm 1)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Quality of Life Measures from Baseline</measure>
    <time_frame>12 months</time_frame>
    <description>Comparison in change from baseline measured by SF-36 Survey after delivery of 4 versus 8 doses of study product (Arm 1 versus Arm 3)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Hypertension,Pulmonary</condition>
  <arm_group>
    <arm_group_label>Placebo followed by Autologous EPCs transfected with eNOS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 monthly IV injections of Placebo (Plasma-Lyte A) during Course 1 followed by 4 monthly IV injections of Autologous EPCs transfected with human eNOS (total of 80 million cells) during Course 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Autologous EPCs transfected with eNOS followed by Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 monthly IV injections of Autologous EPCs transfected with human eNOS (total of 80 million cells) during Course 1 followed by 4 monthly IV injections of Placebo (Plasma-Lyte A) during Course 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Autologous EPCs transfected with eNOS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 monthly IV injections of Autologous EPCs transfected with human eNOS in Course 1 followed by 4 monthly injections of Autologous EPCs transfected with human eNOS in Course 2 (total of 160 million cells)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo followed by Autologous EPCs transfected with human eNOS</intervention_name>
    <description>4 doses of placebo in first 6 months followed by 4 doses of autologous EPCs transfected with eNOS in second 6 months</description>
    <arm_group_label>Placebo followed by Autologous EPCs transfected with eNOS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Autologous EPCs transfected with human eNOS followed by Placebo</intervention_name>
    <description>4 doses of autologous EPCs transfected with eNOS in first 6 months followed by 4 doses of placebo in second 6 months</description>
    <arm_group_label>Autologous EPCs transfected with eNOS followed by Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Autologous EPCs transfected with human eNOS</intervention_name>
    <description>4 doses of autologous EPCs transfected with eNOS in first 6 months which is repeated in second 6 months</description>
    <arm_group_label>Autologous EPCs transfected with eNOS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 18 years, ≤ 80 years&#xD;
&#xD;
          -  Established diagnosis of PAH due to the following:&#xD;
&#xD;
               -  Idiopathic or heritable PAH;&#xD;
&#xD;
               -  Scleroderma associated PAH (limited or diffuse);&#xD;
&#xD;
               -  Drugs (anorexigens) or toxins;&#xD;
&#xD;
               -  Congenital heart defects (atrial septal defects, ventricular septal defects, and&#xD;
                  patent ductus arteriosus) repaired ≥ 1 years&#xD;
&#xD;
          -  WHO functional class II, III, or IV on appropriate stable therapy for PAH for at least&#xD;
             3 months prior to the screening period and up until randomization, apart from&#xD;
             modification of anticoagulant or diuretic dosages, or small adjustments in&#xD;
             prostaglandin dose that are considered by the Investigator to be consistent with&#xD;
             stable parenteral therapy.&#xD;
&#xD;
          -  Able to walk unassisted (oxygen use allowed). Aids for carrying oxygen (such as a&#xD;
             wheel chair or walker) are permitted provided they are not also required as mobility&#xD;
             aids.&#xD;
&#xD;
          -  An average 6-Minute Walk Distance (6MWD) of ≥ 125 meters and ≤ 440 meters on two&#xD;
             consecutive tests during the Screening period&#xD;
&#xD;
          -  Previous diagnostic right heart cardiac catheterization (RHC) at the time of PAH&#xD;
             diagnosis with findings consistent with PAH: specifically, mean pulmonary arterial&#xD;
             pressure (mPAP) ≥ 25 mmHg (at rest); pulmonary vascular resistance (PVR) ≥ 3 WU;&#xD;
             pulmonary capillary wedge pressure (PCWP) (or left ventricular end diastolic pressure)&#xD;
             ≤12 mmHg if PVR ≥ 3 to &lt; 5 WU, or pulmonary capillary wedge pressure (PCWP) (or left&#xD;
             ventricular end diastolic pressure) ≤ 15 mmHg if PVR ≥ 5 WU. If repeat testing has&#xD;
             occurred since initial diagnosis, the most recent results should be used.&#xD;
&#xD;
          -  Echocardiography performed within 12 months prior to the Screening Period confirming a&#xD;
             left atrial volume index (LAVI) of ≤ 34 ml/m2 and the absence of any clinically&#xD;
             significant left heart disease including evidence of more than mild left-sided&#xD;
             valvular heart disease, systolic or diastolic left ventricular dysfunction&#xD;
&#xD;
          -  Ventilation and perfusion (VQ) nuclear scan performed as part of the initial workup to&#xD;
             establish the diagnosis of PAH showing absence (i.e. low probability) of pulmonary&#xD;
             embolism. If repeat testing has occurred since initial diagnosis, the most recent&#xD;
             results should be used. In the absence of a VQ scan to establish eligibility, a CT&#xD;
             angiogram that has been reviewed by a radiologist with expertise in the work up for&#xD;
             pulmonary endarterectomy and deemed negative for chronic thromboembolic disease may be&#xD;
             used instead.&#xD;
&#xD;
          -  Pulmonary function tests conducted within 2 years prior to the Screening Period to&#xD;
             confirm: total lung capacity (TLC) ≥ 65% the predicted value; and forced expiratory&#xD;
             volume at one second (FEV1) of ≥ 65% the predicted value&#xD;
&#xD;
          -  Must have a resting arterial oxygen saturation (SaO2) ≥88% with or without&#xD;
             supplemental oxygen as measured by pulse oximetry at the Screening Visit&#xD;
&#xD;
          -  Must not be enrolled in an exercise training program for pulmonary rehabilitation&#xD;
             within 3 months prior to the Screening Visit and must agree not to enroll in an&#xD;
             exercise training program for pulmonary rehabilitation during the Screening Period and&#xD;
             the first 6 months of the study. Participants enrolled in an exercise program for&#xD;
             pulmonary rehabilitation 3 months prior to screening may enter the study if they agree&#xD;
             to maintain their current level of rehabilitation for the first 6 months of the study&#xD;
&#xD;
          -  Women of child-bearing potential (defined as less than 1 year post-menopausal and not&#xD;
             surgically sterile) must be practicing abstinence or using two highly effective&#xD;
             methods of contraception (defined as a method of birth control that results in a low&#xD;
             failure rate, i.e., less than 1% per year, such as approved hormonal contraceptives,&#xD;
             barrier methods [such as a condom or diaphragm] used with a spermicide, or an&#xD;
             intrauterine device). Subjects must have a negative ß-hCG pregnancy test during the&#xD;
             Screening period and negative urine pregnancy test results at all other study visits&#xD;
&#xD;
          -  Must be willing and able to comply with study requirements and restrictions.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or lactating&#xD;
&#xD;
          -  PAH related to any condition not covered under inclusion criteria, including but not&#xD;
             limited to pulmonary venous hypertension, pulmonary veno-occlusive disease, pulmonary&#xD;
             capillary hemangiomatosis, or chronic thromboembolic pulmonary hypertension&#xD;
&#xD;
          -  Evidence of more than mild interstitial lung disease on Chest CT within the last 5&#xD;
             years (last 3 years for patients with scleroderma associated PAH)&#xD;
&#xD;
          -  Treatment with an investigational drug, device or therapy within 3 months prior to the&#xD;
             screening period or is scheduled to receive an investigational drug, device or therapy&#xD;
             during the course of the study&#xD;
&#xD;
          -  Any musculoskeletal disease or any other disease that would significantly limit&#xD;
             ambulation&#xD;
&#xD;
          -  Unrepaired or recently repaired (&lt; 1 year) congenital systemic-to-pulmonary shunt&#xD;
             other than patent foramen ovale&#xD;
&#xD;
          -  Patients having three or more of the following four AMBITION study HFpEF risk factors&#xD;
             will be excluded:&#xD;
&#xD;
               -  BMI ≥ 30 kg/m2,&#xD;
&#xD;
               -  History of essential hypertension,&#xD;
&#xD;
               -  Diabetes mellitus (any type)&#xD;
&#xD;
               -  Historical evidence of significant coronary artery disease (CAD) by ANY ONE of&#xD;
                  the following:&#xD;
&#xD;
                    -  History of MI&#xD;
&#xD;
                    -  History of PCI&#xD;
&#xD;
                    -  Prior coronary angiography evidence of CAD (&gt;50% stenosis in ≥1 vessel)&#xD;
&#xD;
                    -  Previous positive Stress Test&#xD;
&#xD;
                    -  Previous CABG&#xD;
&#xD;
                    -  Stable angina&#xD;
&#xD;
          -  Creatinine clearance &lt;30 ml/min (using the Cockroft-Gault formula) or requires&#xD;
             hemodialysis&#xD;
&#xD;
          -  Inability to undergo the apheresis procedure due to poor venous access or laboratory&#xD;
             tests that are not within acceptable ranges (not including INR for patients on&#xD;
             Coumadin)&#xD;
&#xD;
          -  Childs-Pugh class C liver cirrhosis&#xD;
&#xD;
          -  Previous atrial septostomy&#xD;
&#xD;
          -  Any other clinically significant illness or abnormal laboratory values (measured&#xD;
             during the screening period) that, in the opinion of the Investigator, might put the&#xD;
             subject at risk of harm during the study or might adversely affect the interpretation&#xD;
             of the study data&#xD;
&#xD;
          -  Anticipated survival less than 1 year due to concomitant disease&#xD;
&#xD;
          -  History of cancer in the past 5 years (except for low grade and fully resolved&#xD;
             non-melanoma skin cancer)&#xD;
&#xD;
          -  Results during screening consistent with current infection with HIV, Hepatitis B(HBV)&#xD;
             or C(HCV), human T-cell lymphotropic virus (HTLV- I/II) or syphilis&#xD;
&#xD;
          -  Systemic arterial systolic blood pressure &lt; 85 mm Hg&#xD;
&#xD;
          -  Known allergy to gentamicin or amphotericin&#xD;
&#xD;
          -  Patients who have participated in any gene therapy study or an angiogenic growth&#xD;
             factor protein study&#xD;
&#xD;
          -  Patients unable to provide informed consent and comply with the visit schedule.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Peter Lougheed Center, University of Calgary</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T1Y 6J4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vancouver General Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 1M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Joseph's Hospital (McMaster University)</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 4A6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>London Health Sciences Center</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5W9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Ottawa Heart Institute</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1Y 4W7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toronto General Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2N2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>January 2023</verification_date>
  <study_first_submitted>December 15, 2016</study_first_submitted>
  <study_first_submitted_qc>December 19, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 23, 2016</study_first_posted>
  <last_update_submitted>January 9, 2023</last_update_submitted>
  <last_update_submitted_qc>January 9, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">January 11, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension, Pulmonary</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT03001414
org study id: CT-PAH002
nct id: NCT03001414
lead sponsor: 
collaborator: 
has dmc: Yes
is fda regulated drug: No
is fda regulated device: No
The SAPPHIRE clinical trial seeks to establish the efficacy and safety of repeated monthly
      dosing of autologous EPCs transfected with human eNOS (heNOS) in patients with symptomatic
      severe PAH on available PAH-targeted medical therapy.
SAPPHIRE will use autologous progenitor cell-based gene delivery to enhance lung
      microvascular repair and regeneration in patients with severe symptomatic PAH. A total of 45
      patients will be enrolled in this multi-centre, late phase, randomized, double-blind,
      placebo-controlled, 3-arm protocol. Up to nine centres across Canada will participate.

      Consented study participants who meet all eligibility criteria during the screening period
      will be scheduled to undergo apheresis. Following successful apheresis collection and receipt
      of the cell samples by the cell manufacturing facility, randomization will take place though
      a web-based system. Manufacturing of the cell therapy product will then be performed by the
      cell manufacturing facility according to the assigned treatment allocation:

      Arm 1: Placebo (Plasma-Lyte A; 4 monthly IV infusions) in Course 1 (1st 6 months) followed by
      Autologous EPCs transfected with human eNOS in Course 2 (2nd 6 months; 4 monthly IV
      infusions)

      Arm 2: Autologous EPCs transfected with human eNOS in Course 1 (1st 6 months; 4 monthly IV
      infusions) followed by Placebo (Plasma-Lyte A) in Course 2 (2nd 6 months; 4 monthly IV
      infusions)

      Arm 3: Autologous EPCs transfected with human eNOS in Course 1 (1st 6 months; 4 monthly IV
      infusions) followed by a repeat dosing with Autologous EPCs transfected with human eNOS in
      Course 2 (2nd 6 months; 4 monthly IV infusions)

      Approximately 5-9 days later, the study product will be transported to the investigative site
      where the initial treatment will be delivered to the study participant in an outpatient
      setting which is equipped for continuous monitoring of vital signs and oxygen saturation.
      Participants will subsequently be monitored for a minimum of 1 hour and discharged from the
      clinic once judged by the study investigator to be clinically stable.

      Treatment and follow-up assessments will take place over a 12-month period (11 study visits
      in total). Once the 12-month trial data collection is completed, the trial will convert to a
      registry with the goal of collecting long-term safety information through annual telephone
      contacts for 10 years. Participants will be permitted to enroll in other clinical trials
      during the registry period.
allocation: Randomized
intervention model: Crossover Assignment
primary purpose: Treatment
masking: Triple (Participant, Care Provider, Investigator)
measure: Change in 6 Minute Walk Distance (6MWD) from Baseline
time frame: 6 months
description: Comparison of change from baseline after delivery of 4 doses of study product (Arms 2 and 3 versus Arm 1)
measure: Change in 6 Minute Walk Distance (6MWD) from Baseline
time frame: 12 months
description: Comparison of change from baseline after delivery of 4 versus 8 doses of study product (Arms 1 versus Arm 3)
measure: Change in 6 Minute Walk Distance (6MWD) from Baseline
time frame: 3 and 9 months
description: Comparison of change from baseline to assess durability of any measured improvement (Arm 2 only)
measure: Change in Pulmonary Vascular Resistance from Baseline
time frame: 6 months
description: Comparison of change from baseline after 4 doses of study product (Arms 2 and 3 versus Arm 1)
measure: Change in Pulmonary Vascular Resistance from Baseline
time frame: 12 months
description: Comparison of change from baseline after delivery of 4 versus 8 doses of study product (Arm 1 versus Arm 3)
measure: Change in Pulmonary Vascular Resistance from Baseline
time frame: 3 and 9 months
description: Comparison of change from baseline to assess durability of any measured improvement (Arm 2 only)
measure: Number of Deaths or Clinical Worsening of Pulmonary Arterial Hypertension
time frame: 6 months
description: Comparision of number measured from baseline (Arms 2 and 3 versus Arm 1). Clinical worsening will be defined by any of the following: all-cause mortality, hospitalization due to worsening cardiopulmonary status attributable to progression of disease, decrease in 6MWD by ≥ 15%, worsening of WHO functional class
measure: Number of Deaths or Clinical Worsening of Pulmonary Arterial Hypertension
time frame: 12 months
description: Comparison of number measured from baseline after delivery of 4 versus 8 doses of study product (Arm 1 versus Arm 3). Clinical worsening will be defined by any of the following: all-cause mortality, hospitalization due to worsening cardiopulmonary status attributable to progression of disease, decrease in 6MWD by ≥ 15%, worsening of WHO functional class
measure: Change in Echocardiography Right Ventricular (RV) Function Measures from Baseline
time frame: 6 months
description: Comparison of change from baseline after 4 doses of study product (Arms 2 and 3 versus Arm 1)
measure: Change in Echocardiography Right Ventricular (RV) Function Measures from Baseline
time frame: 12 months
description: Comparison of change from baseline after delivery of 4 versus 8 doses of study product (Arm 1 versus Arm 3)
measure: Change in Magnetic Resonance Imaging Right Ventricular (RV) Function Measures from Baseline
time frame: 6 months
description: Comparison of change from baseline after delivery of 4 doses of study product (Arms 2 and 3 versus Arm 1)
measure: Change in Magnetic Resonance Imaging Right Ventricular (RV) Function Measures from Baseline
time frame: 12 months
description: Comparison of change from baseline after delivery of 4 versus 8 doses of study product (Arm 1 versus Arm 3)
measure: Change in Quality of Life Measures from Baseline
time frame: 6 months
description: Comparison of change from baseline measured by SF-36 Survey after delivery of 4 doses of study product (Arms 2 and 3 versus Arm 1)
measure: Change in Quality of Life Measures from Baseline
time frame: 12 months
description: Comparison in change from baseline measured by SF-36 Survey after delivery of 4 versus 8 doses of study product (Arm 1 versus Arm 3)
arm group label: Placebo followed by Autologous EPCs transfected with eNOS
arm group type: Experimental
description: 4 monthly IV injections of Placebo (Plasma-Lyte A) during Course 1 followed by 4 monthly IV injections of Autologous EPCs transfected with human eNOS (total of 80 million cells) during Course 2
arm group label: Autologous EPCs transfected with eNOS followed by Placebo
arm group type: Experimental
description: 4 monthly IV injections of Autologous EPCs transfected with human eNOS (total of 80 million cells) during Course 1 followed by 4 monthly IV injections of Placebo (Plasma-Lyte A) during Course 2
arm group label: Autologous EPCs transfected with eNOS
arm group type: Experimental
description: 4 monthly IV injections of Autologous EPCs transfected with human eNOS in Course 1 followed by 4 monthly injections of Autologous EPCs transfected with human eNOS in Course 2 (total of 160 million cells)
intervention type: Biological
intervention name: Placebo followed by Autologous EPCs transfected with human eNOS
description: 4 doses of placebo in first 6 months followed by 4 doses of autologous EPCs transfected with eNOS in second 6 months
arm group label: Placebo followed by Autologous EPCs transfected with eNOS
intervention type: Biological
intervention name: Autologous EPCs transfected with human eNOS followed by Placebo
description: 4 doses of autologous EPCs transfected with eNOS in first 6 months followed by 4 doses of placebo in second 6 months
arm group label: Autologous EPCs transfected with eNOS followed by Placebo
intervention type: Biological
intervention name: Autologous EPCs transfected with human eNOS
description: 4 doses of autologous EPCs transfected with eNOS in first 6 months which is repeated in second 6 months
arm group label: Autologous EPCs transfected with eNOS
criteria: 
gender: All
minimum age: 18 Years
maximum age: 80 Years
healthy volunteers: No
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
country: Canada
responsible party type: Sponsor
mesh term: Hypertension, Pulmonary
mesh term: Hypertension
sharing ipd: No